Vikash Khurana, MD
Interventional Cardiology · Vincennes, INNPI 1649341025
Payments from drug & device makers
Across 242 payments — averaging $25.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Actelion Pharmaceuticals US, Inc.$625
- Merck$443
- AstraZeneca$393
- Amgen$360
- Boehringer Ingelheim$240
- plus $2K from 30 others
What the payments were for
- Travel & lodging$1,96932%
- Food & beverage$4,10867%
- Education$952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 25 | $2,553 |
| Actelion Pharmaceuticals US, Inc. | 33 | $625 |
| Merck | 30 | $443 |
| AstraZeneca | 16 | $393 |
| Amgen | 25 | $360 |
| Boehringer Ingelheim | 14 | $240 |
| Novartis | 13 | $215 |
| Johnson & Johnson | 19 | $165 |
| Novo Nordisk | 8 | $145 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $113 |
| Abiomed | 3 | $93 |
| Shockwave Medical, Inc | 4 | $75 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $67 |
| Philips North America LLC | 4 | $63 |
| Bayer | 3 | $57 |
| Pfizer | 4 | $56 |
| Sanofi | 3 | $54 |
| Abbott | 2 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| United Therapeutics Corporation | 2 | $41 |
| Terumo Medical Corporation | 2 | $38 |
| Pulmonx Corporation | 1 | $32 |
| Acist Medical Systems, Inc. | 1 | $27 |
| GSK | 2 | $26 |
| Amarin Pharma, Inc. | 2 | $25 |
| Grifols USA, LLC | 2 | $22 |
| Mylan Specialty L.p. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Resmed Corp | 1 | $17 |
| Preventice Services, LLC | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Baxter Healthcare | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,172 in reported general payments places this provider in the 40th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 816 | $647,351 |
| EntrestoSacubitril/Valsartan | 427 | $286,836 |
| XareltoRivaroxaban | 271 | $226,117 |
| Repatha SureclickEvolocumab | 234 | $181,985 |
| FarxigaDapagliflozin Propanediol | 156 | $133,757 |
| BrilintaTicagrelor | 102 | $59,376 |
| JardianceEmpagliflozin | 47 | $33,019 |
| Praluent PenAlirocumab | 37 | $19,443 |
| VerquvoVericiguat | 18 | $11,782 |
| Metoprolol Succinate | 1,123 | $11,560 |
| Atorvastatin Calcium | 1,248 | $9,823 |
| ClopidogrelClopidogrel Bisulfate | 726 | $8,009 |
| Ranolazine ErRanolazine | 88 | $7,499 |
| Repatha SyringeEvolocumab | 18 | $6,349 |
| CorlanorIvabradine Hcl | 13 | $6,330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $56 | $647,351816 claims |
| NovartisEntresto | $215 | $286,836427 claims |
| Johnson & JohnsonXarelto | $165 | $226,117271 claims |
| AstraZenecaFarxiga, Brilinta | $393 | $193,133258 claims |
| Boehringer IngelheimJardiance | $240 | $33,01947 claims |
| MerckVerquvo | $443 | $11,78218 claims |
| AmgenCorlanor | $360 | $6,33013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Vincennes
- James HermillerIndianapolis$2.8M
- Jithendra ChoudaryRichmond$1.6M
- Jeffrey BreallIndianapolis$955K
- Samer AbbasEast Chicago$625K
- Jarrod FrizzellEvansville$559K
- Brian BigelowIndianapolis$444K
- Saeed ShaikhIndianapolis$366K
- Dean FerreraEast Chicago$298K
- Woodrow CoreyIndianapolis$262K
- Navneet LatherNoblesville$223K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.